logo
DrayTek Selects MaxLinear 2.5G Ethernet Switches for Multi-Port Networking Web-Management Switches

DrayTek Selects MaxLinear 2.5G Ethernet Switches for Multi-Port Networking Web-Management Switches

Business Wire19-05-2025
CARLSBAD, Calif.--(BUSINESS WIRE)-- MaxLinear, Inc. (Nasdaq: MXL) a global leader in wired network solutions, today announced that DrayTek, a leading developer of high performance networking equipment, has selected the MxL86252S and MxL86282S 2.5G Ethernet Switch SoCs for its next generation 7- and 10-port Ethernet switches. MaxLinear will demonstrate its 2.5G solutions at Computex 2025, May 20-23, 2025 in Taipei, Taiwan.
The MxL86252S and MxL86282S support HTTPS protocol for enhanced data security and robust encrypted connections to support the growing demand for secure, high-performance networking in applications such as digital signage, video conferencing, and esports broadcasting. The switches also offer advanced ACL rule configurations, giving users greater flexibility to manage and secure their network environments. Additionally, IGMPv3 support enables efficient multicast traffic handling, unlocking next-generation applications across enterprise and media-rich environments.
"Today's networks demand more than just speed—they require intelligent features and robust security," said Vikas Choudhary, Vice President of Connectivity and Storage business at MaxLinear. "Our portfolio of 2.5G Ethernet Switches deliver on both fronts, with 2.5G Ethernet speed for handling bandwidth-intensive applications, HTTPS support for secure data transmission, flexible ACL rules for precise network control, and IGMPv3 for advanced multicast capabilities. These features enable our customers to build compact, energy-efficient switches that are ready for modern, high-performance applications."
'By leveraging MaxLinear's 2.5G Ethernet Switch SoCs, we can offer our customers high port count switches that are not only compact and energy-efficient but also equipped to handle increasing data traffic demands,' said Henry Lo, Head of Product Planning at DrayTek. 'This is another example of our commitment to deliver networking technology that enhances connectivity and performance for both consumers and businesses.'
MxL86282S Key Features and Benefits:
Highly Integrated: Eight integrated Ethernet 2.5GBASE-T PHYs that support four data rates: 2500, 1000, 100, and 10Mbps. Plus, two optional 10G SERDES uplink ports that provide additional flexibility for network configurations and one integrated CPU to enable web-smart applications.
Low Power Consumption: Under 700mW per PHY. Supports the Energy-Efficient Ethernet (EEE) feature to reduce idle mode power consumption. Offers additional power savings modes for short cables, through EEE, and no-link detection. Power saving at the system level is also possible with the wake-on-LAN (WoL) feature.
Switching Performance: Unblocking wire-speed switching between all ports to support all ports at full rate without packet loss.
Future-Proof Features: A programmable packet parser and a powerful classification engine allow future-proof designs that enable various data traffic types. The MxL86282C supports IPv4 and IPv6, HTTPS security, IGMPv1/IGMPv2/IGMPv3 multicast forwarding, and MLDv1/MLDv2 snooping.
Advanced Features: Includes: VLAN, QinQ, QoS, loop detection, ACL, and traffic shaping.
The MxL86282S and MxL86252S are available now in RoHS compliant, green/halogen free 12mm x 12mm BGA packages. Visit MxL86252S and MxL86282S for additional information or to request samples.
For more information on MaxLinear's products:
About MaxLinear, Inc.
MaxLinear, Inc. (Nasdaq: MXL) is a leading provider of radio frequency (RF), analog, digital, and mixed-signal integrated circuits for access and connectivity, wired and wireless infrastructure, and industrial and multimarket applications. MaxLinear is headquartered in Carlsbad, California. For more information, please visit https://www.maxlinear.com/.
Cautionary Note About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning or implying future financial performance, statements relating to MaxLinear's ethernet switches and the functionality, performance, benefits, and market opportunity for such product, statements by our Vice President of Connectivity and Storage business and statements by the Head of Product Planning of DrayTek. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements and our future financial performance and operating results forecasts generally. Forward-looking statements are based on management's current, preliminary expectations and are subject to various risks and uncertainties. In particular, our future operating results are substantially dependent on our assumptions about market trends and conditions. Additional risks and uncertainties affecting our business, future operating results and financial condition include, without limitation; risks relating to the development, testing, and commercial introduction of new products and product functionalities; risks relating to our relationship with Draytek; risks relating to our terminated merger with Silicon Motion and related arbitration and class action complaint and the risks related to potential payment of damages; the effect of intense and increasing competition; increased tariffs, export controls or imposition of other trade barriers; impacts of global economic conditions; the cyclical nature of the semiconductor industry; a significant variance in our operating results and impact on volatility in our stock price, and our ability to sustain our current level of revenue, which has previously declined, and/or manage future growth effectively, and the impact of excess inventory in the channel on our customers' expected demand for certain of our products and on our revenue; escalating trade wars, military conflicts and other geopolitical and economic tensions among the countries in which we conduct business; our ability to obtain or retain government authorization to export certain of our products or technology; risks related to the loss of, or a significant reduction in orders from major customers; costs of legal proceedings or potential violations of regulations; information technology failures; a decrease in the average selling prices of our products; failure to penetrate new applications and markets; development delays and consolidation trends in our industry; inability to make substantial research and development investments; delays or expenses caused by undetected defects or bugs in our products; substantial quarterly and annual fluctuations in our revenue and operating results; failure to timely develop and introduce new or enhanced products; order and shipment uncertainties; failure to accurately predict our future revenue and appropriately budget expenses; lengthy and expensive customer qualification processes; customer product plan cancellations; failure to maintain compliance with government regulations; failure to attract and retain qualified personnel; any adverse impact of rising interest rates on us, our customers, and our distributors and related demand; risks related to compliance with privacy, data protection and cybersecurity laws and regulations; risks related to conforming our products to industry standards; risks related to business acquisitions and investments; claims of intellectual property infringement; our ability to protect our intellectual property; risks related to security vulnerabilities of our products; use of open source software in our products; and failure to manage our relationships with, or negative impacts from, third parties.
In addition to these risks and uncertainties, investors should review the risks and uncertainties contained in our filings with the Securities and Exchange Commission, including our Current Reports on Form 8-K, as well as the information to be set forth under the caption "Risk Factors" in MaxLinear's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. All forward-looking statements are based on the estimates, projections and assumptions of management as of the date of this press release, and MaxLinear is under no obligation (and expressly disclaims any such obligation) to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Business Wire

time10 minutes ago

  • Business Wire

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into securities purchase agreements with several institutional and accredited investors (the "Purchasers") for the purchase and sale of 990 shares of the Company's Series B Convertible Preferred Stock (the 'Preferred Stock') and warrants (the 'Private Placement Warrants') to purchase approximately 6.7 million shares of common stock (the 'Private Placement'). The Company shall use the net proceeds from the Private Placement and Warrant Inducement for working capital and general corporate purposes. The shares of Preferred Stock have a stated value of $1,000 per share and are initially convertible into an aggregate of approximately 4.3 million shares of common stock at a conversion price of $0.23 per share. The Private Placement Warrants will be exercisable following the date on which the Company obtains stockholder approval of the exercise thereof at an initial exercise price of $0.352 per share and expire five years from the original exercise date. The Company also announced today it has entered into a warrant exercise agreement with an existing accredited investor to exercise (i) outstanding warrants to purchase 450,000 shares of the Company's shares of common stock that were issued in August 2024 (the 'August Warrants') and (ii) outstanding warrants to purchase 650,000 shares of the Company's common stock that were issued in October 2024 (the 'October Warrants' and together with the August Warrants, the 'Existing Warrants'), which reduced the exercise prices of the August Warrants from $1.50 to $0.23 per share and the October Warrants from $1.25 to $0.23 per share and provided for the issuance to such investor of new unregistered warrants (the 'New Warrants') to purchase up to an aggregate of 1.43 million shares of the Company's common stock in consideration for the immediate exercise in full of the Existing Warrants for gross cash proceeds to the Company of approximately $253,000 (the 'Warrant Inducement'). The New Warrants will have an exercise price of $0.352 per share and will be initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained and will expire five years from the date of such approval. The closing of the Private Placement and Warrant Inducement is expected to occur on or about August 14, 2025, subject to the satisfaction of customary closing conditions. The expected aggregate proceeds (before expenses) of the Private Placement and Warrant Inducement will be approximately $1.2 million. The Company shall use the net proceeds from the Private Placement and Warrant Inducement for working capital and general corporate purposes. WallachBeth Capital LLC is acting as the sole placement agent for the Private Placement and financial advisor for the Warrant Inducement. The securities described above will be offered in a private placement exempt from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and Regulation D promulgated thereunder and in a transaction not involving a public offering and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Preferred Stock, the Private Placement Warrants and New Warrants within 15 calendar days after the closing date. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About CyPath® Lung CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the closing of the offering on August 14, 2025. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to close the offering when anticipated and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Alen Celebrates 20 Years of Innovation and Leadership in Air Purification For Home, School and Work
Alen Celebrates 20 Years of Innovation and Leadership in Air Purification For Home, School and Work

Business Wire

time10 minutes ago

  • Business Wire

Alen Celebrates 20 Years of Innovation and Leadership in Air Purification For Home, School and Work

AUSTIN, Texas--(BUSINESS WIRE)-- Alen, a leader in the air purification industry, today celebrates 20 years of creating best-in-class air purifiers that ensure the health and safety for millions of Americans. The Austin-based company has become a trusted name in clean air solutions since its founding in 2005, recognized by leading industry and scientific experts for its powerful technology, thoughtful design and its deep commitment to healthier living. 'Alen began with one goal in mind. Make clean air simple, effective, and accessible, for people and pets,' said Warburg Lee, Founder and CEO of Alen. 'Since then, both outdoor and indoor air quality have worsened due to wildfires, increased allergens, and viruses, making our mission even more critical. We're a health and wellness company, not just an air purifier company, with a mandate to create healthy living and working environments. From our earliest models to our most recent advanced purifier models, our north star is that we remove 99.9 percent of airborne particulates while operating quietly in the background to protect what matters most.' 20 years of achievements include: Growing from start-up to nationally recognized brand with over 50 team members, availability in all 50 states, serving more than 2 million customers worldwide, and developing the fifth generation of advanced air purifier systems with new products launching in October 2025. Meeting critical third-party standards, including certifications from ENERGY STAR, Quiet Mark, SleepScore Labs, and the Asthma and Allergy Friendly Program. Products are tested to remove up to 99.9 percent of airborne particles down to 0.1 microns. Sought-after by national retailers including Lowe's and Amazon to carry Alen products because they are a trusted brand for homes, schools, and businesses across the country. Continued excellence in technology, developing proprietary technology, industry-first features, and responsive design with intelligent sensors and proprietary airID technology that detects and responds to real-time air quality changes, automatically adjusting to remove pollutants like dust, smoke, and chemicals for cleaner, healthier air. Day-one pursuit of design to fit the aesthetics of modern living. Alen purifiers blend seamlessly into bedrooms, offices, classrooms, and large commercial spaces with multiple sizes, ultra-quiet performance, and customizable designer panels. Alen's mission to improve indoor air became a national movement for wellness. Alen continues to lead with purpose, innovation, and a long-standing commitment to help people breathe better and live healthier. Alen is preparing to introduce new models later this year, building on its reputation for premium air purification and breakthrough technology. These upcoming releases will reinforce its position as a leader in clean air solutions. Alen is poised to deliver greater impact across both retail and business-to-business markets, backed by ongoing innovation, supply chain strength, and strategic commercial partnerships. To explore Alen's full range of air purification solutions, visit About Alen Alen is an Austin-based innovator of high-performance air purifiers, committed to creating healthier indoor environments through advanced, scientifically validated technology. Alen's purifiers use True HEPA filters and are independently certified by Quiet Mark, the Asthma & Allergy Friendly® Certification Program, SleepScore Labs, and ENERGY STAR® for delivering best-in-class air purification, energy efficiency, ultra-quiet operation, and improved sleep quality. Alen's mission to enhance quality of life in homes, workplaces, and shared spaces is driven by the belief that wellness begins with pure air. Alen empowers individuals and families to lead healthier lives with cleaner, safer air and greater peace of mind through proprietary features like airID smart sensor technology and a commitment to lifetime reliability.

BM3EAC Corp. 2025 Semi-Annual Report
BM3EAC Corp. 2025 Semi-Annual Report

Business Wire

time10 minutes ago

  • Business Wire

BM3EAC Corp. 2025 Semi-Annual Report

AMSTERDAM--(BUSINESS WIRE)--BM3EAC Corp. (the 'Company'), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2025 to 30 June 2025. The semi-annual report can be downloaded from the Company's website via the following link: This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER The Company's semi-annual report referenced in this announcement may include forward-looking statements, which are based on the Company's current expectations and projections regarding a business combination, the business, the economy and other future conditions of the Company and speak only as of the date hereof. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's business, results of operations, financial position, liquidity, prospects, growth or strategies. The Company shall have no obligation to update any forward-looking statements after the date of this announcement. This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does not contain or constitute an offer of securities for sale or an invitation or offer to the public for securities in any jurisdiction. In the EEA, this announcement is only directed at persons who are 'qualified investors' within the meaning of Article 2(e) of the Prospectus Regulation (EU 2017/1129) as amended. In the United Kingdom, this announcement is directed only at 'qualified investors' within the meaning of Article 2(e) of the Prospectus Regulation (EU) No 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store